Ehave, Inc., a healthcare company dedicated to empowering the mental health community with next-generation digital solutions, and MedReleaf Corp. have announced that the companies have entered into a partnership to develop n app utilizing the Ehave Connect mental health informatics platform to advance the study and therapeutic use of medical cannabis.

Ehave Connect enables developers, and ultimately prescribers, of medical cannabis to design and monitor treatment plans, track patient compliance, and verify treatment outcomes in a reliable and objective manner.

Together, Ehave and MedReleaf seek to v optimize the use of MedReleaf’s medical cannabis products as therapeutic treatments for various mental health conditions. Initially, the companies will use Ehave Connect to manage treatment plans and track patient outcomes as part of a clinical trial to evaluate medical cannabis’s potential ability to provide relief to persons suffering from post-traumatic stress disorder (“PTSD”).  Ultimately, it is anticipated that the MedReleaf App based on the Ehave Connect platform can be used to monitor every step of the medical cannabis treatment life cycle, from diagnosis and treatment planning to medication adherence and outcomes verification.

Validating therapeutic dosing and administration of cannabis-based therapies, while paramount to developing new products and promoting clinical acceptance, remains a challenge, particularly in mental health indications where patient outcomes are difficult to track. Currently, the medical cannabis industry requires more clinical data for prescribers to draw from when advising patients on treatment plans, as well as reliable systems to track patient adherence and outcomes.

Ehave Connect provides a suite of data-rich patient management and assessment tools that may enable more accurate and efficient study of medical cannabis and help establish objective treatment guidelines that Physicians can rely upon when prescribing cannabis therapies.

“By 2024, more than 450,000 Canadian patients will be prescribed medical cannabis, creating a market worth more than $1.3 billion, according to Health Canada estimates,” said Prateek Dwivedi, President and CEO of Ehave. “This large and emerging industry is in desperate need of a technology platform to capture and deliver reliable clinical data to satisfy the needs of patients, clinicians, regulators, and payors. We’re excited to initiate our work with a company of MedReleaf’s stature and prominence in the industry, which will serve as an important first step in showcasing how Ehave Connect will be able to support the development and use of medical cannabis for the full breadth of indications where such therapies are applied.”

“Ehave Connect is perfectly suited to help evaluate the benefits of medical cannabis,” said Neil Closner, CEO of MedReleaf. “We look forward to working with Ehave to validate our cannabis therapies across multiple health conditions, especially mental health and pain conditions where treatment benefits can be difficult to ascertain.